ArticleBMC pharmacology & toxicology2025
Appropriateness of proton pump inhibitor prescription for prevention of gastrointestinal bleeding in patients receiving warfarin: a real world, database study.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProton pump inhibitors (PPIs) are recommended for preventing gastrointestinal bleeding (GIB) in patients on warfarin who have risk factors. However, real-world data on the appropriateness of these prescriptions are limited. This study aimed to evaluate the appropriateness of PPI prescriptions for GIB prevention in a cohort of patients receiving warfarin.
methodsWe conducted a retrospective cohort study at a university hospital using data from 2018 to 2023. Adult patients (≥ 18 years) on continuous warfarin therapy were included. We identified four key guideline-recommended indications for PPI prophylaxis: (1) age > 65 years, (2) history of peptic ulcer disease (PUD), (3) concurrent antiplatelet use, and (4) concurrent NSAID/corticosteroid use. Guideline-adherent care was assessed by quantifying two key metrics: under-prescription (absence of a PPI in patients with ≥ 1 indication) and over-prescription (presence of a PPI in patients with no indications).
resultsOf 2,366 eligible patients, 1,789 (75.6%) had at least one indication for PPI therapy. Within this high-risk group, 1,178 patients (65.8%) were under-prescribed. Among the 577 patients with no GIB risk indications, 138 (23.9%) were over-prescribed. The rate of PPI use in high-risk patients increased with the number of risk factors (from 26.8% with one factor to 66.7% with four). Patients with a history of PUD had the highest prescription rate (54.4%), while patients aged > 65 years had one of the lowest (36.2%).
conclusionsIn this real-world cohort, PPIs were significantly under-prescribed for GIB prevention in high-risk patients on warfarin, with nearly two-thirds not receiving indicated therapy. Conversely, over-prescription occurred in nearly a quarter of low-risk patients. These findings highlight a critical gap in translating guidelines into practice and suggest a need for targeted educational interventions for prescribers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.